Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane？ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status Prescription; Discontinued
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 52222-0001; 63126-902; 69539-159; 45963-613; 63323-763; 16714-137; 47781-595; 68817-134; 42533-111; 68083-179; 72205-062; 60505-6230; 70860-215; 72205-061; 68083-178; 49452-4961; 44567-506; 70747-1003; 69539-158; 0703-3216; 68554-0061; 0703-3218; 65129-1308; 51446-0110; 68001-516; 17359-3055; 69443-022; 0703-3217; 17359-4040; 44567-504; 0703-4768; 0703-3213; 69539-157; 61703-342; 65129-2039; 54893-0007; 24979-710; 70860-200; 44567-505; 62422-0002; 59651-605; 72205-063; 68083-180; 51446-0120; 0703-4764; 17359-4055
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.016784%
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abscess11.01.08.0010.000533%Not Available
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.001042%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.001--Not Available
Acute pulmonary oedema02.05.02.004; 22.01.03.0050.000139%Not Available
Acute respiratory distress syndrome22.01.03.0010.000695%
Acute respiratory failure14.01.04.004; 22.02.06.0010.000347%Not Available
Adenocarcinoma16.16.01.004--Not Available
Adrenal insufficiency05.01.02.001; 14.11.01.004--
Ageusia07.14.03.003; 17.02.07.001--Not Available
Aggression19.05.01.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.0010.001865%Not Available
Alanine aminotransferase increased13.03.01.0030.005595%
Alopecia23.02.02.0010.022112%
Altered state of consciousness17.02.04.001; 19.07.01.0030.002131%Not Available
Alveolitis22.01.01.0010.000799%Not Available
Alveolitis allergic10.01.03.008; 22.01.01.0020.000533%Not Available
Amblyopia06.02.01.001--Not Available
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.0010.031703%
Anaphylactic reaction10.01.07.001; 24.06.03.0060.011988%
Anaphylactic shock10.01.07.002; 24.06.02.0040.013587%Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.0070.001332%Not Available
Aneurysm24.02.01.0010.000208%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 29 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene